These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8747407)

  • 1. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
    Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
    Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
    Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Dec; 6(6):547-51. PubMed ID: 9014204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
    Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
    J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
    Takakubo F; Kuwano A; Kondo I
    Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
    Brøsen K; de Morais SM; Meyer UA; Goldstein JA
    Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.
    Laine K; Tybring G; Bertilsson L
    Clin Pharmacol Ther; 2000 Aug; 68(2):151-9. PubMed ID: 10976546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals.
    Ishizaki T; Sohn DR; Kobayashi K; Chiba K; Lee KH; Shin SG; Andersson T; Regårdh CG; Lou YC; Zhang Y
    Ther Drug Monit; 1994 Apr; 16(2):214-5. PubMed ID: 8009572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.
    Chang M; Tybring G; Dahl ML; Götharson E; Sagar M; Seensalu R; Bertilsson L
    Br J Clin Pharmacol; 1995 May; 39(5):511-8. PubMed ID: 7669487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
    Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
    Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
    De Morais SM; Wilkinson GR; Blaisdell J; Meyer UA; Nakamura K; Goldstein JA
    Mol Pharmacol; 1994 Oct; 46(4):594-8. PubMed ID: 7969038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
    Kimura M; Ieiri I; Wada Y; Mamiya K; Urae A; Iimori E; Sakai T; Otsubo K; Higuchi S
    Br J Clin Pharmacol; 1999 Jan; 47(1):115-9. PubMed ID: 10073749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population.
    Jurima-Romet M; Goldstein JA; LeBelle M; Aubin RA; Foster BC; Walop W; Rode A
    Pharmacogenetics; 1996 Aug; 6(4):329-39. PubMed ID: 8873219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
    Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.